<unk>  is a hydrolytic lysosomal cholesteryl ester and triacylglycerol-specific enzyme that is FDA approved for the treatment of patients with Lysosomal Acid Lipase (LAL) deficiency.   Common adverse reactions include diarrhea, vomiting, fever, rhinitis,anemia, cough, nasopharyngitis, and urticaria (≥30%) in patients with rapidly progressive disease presenting within the first 6 months of life and for pediatric and adult patients the most common adverse reactions include headache,fever, oropharyngeal pain, nasopharyngitis, asthenia, constipation, and nausea (≥8%).
Sebelipase alfa
Asfotase alfa
Cerliponase alfa
Dornase alfa
Pancrelipase
Peginesatide
Reteplase
Drotrecogin alfa